Probiotics can treat hepatic encephalopathy

Medical Hypotheses

Volumn 61, Issue 2, 2003, Pages 307-313

  Solga, Steven F ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; ANTIBIOTIC AGENT; BACTERIAL ENZYME; LACTULOSE; LAXATIVE; PROBIOTIC AGENT; UREASE;

BACTERIAL STRAIN; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; DRUG ABSORPTION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ENZYME INACTIVATION; GASTROINTESTINAL ABSORPTION; HEPATIC ENCEPHALOPATHY; HUMAN; INTESTINE EPITHELIUM; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII; LIVER CLEARANCE; MICROBIAL METABOLISM; MITOCHONDRIAL RESPIRATION; NUTRITIONAL STATUS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STREPTOCOCCUS THERMOPHILUS;

EID: 0043124270     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(03)00192-0     Document Type: Article

References (63)

1. Blei A., Cordoba J. Hepatic encephalopathy. Am J Gastroenterol 2001; 96(7): 1968-1976.
2. Gilberstadt S. J., Gilberstadt H., Zieve L., Buegel B., Collier R. O., Jr, McClam C. J. Psychomotor performance defects in cirrhotic patients without overt encephalopathy. Arch Intern Med 1980; 140: 519-521.
3. Gitlin N., Lewis D. C., Hinkley L. The diagnosis and prevelance of subclinical hepatic encephalopthy m apparently healthy, ambulant, non-shunted patients with cirrhosis. J Hepatol 1986; 3: 75-82.
4. Weissenborn K., Ennen J. C., Schomerus H., Ruckery N., Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001; 34: 768-773.
5. Schomerus H., Hamster W., Blunck H., Reinhard U., Mayer K., Dolle W. Latent portosystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive. Dig Dis Sci 1981; 26: 622-630.
6. Hamster, W. Neuropsychologie der latenten portosystemischen Enzephalopathie. Hebilitationsschrift, Medizinische Fakultat der Eberhard-Karts-Universistat Turbingen, Turbingen, 1982.
7. Groenweg M., Qeuro J. C., De Bruijn I. et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998; 28: 45-49.
8. Conn H. O. Quantifying the severity of hepatic encephalopathy. In: H. O. Conn, Bircher (eds). Hepatic Encephalopathy: Syndromes and Therapies. East Lansing, MI: Medi-Ed Press, 1993: 13-26.
9. Burne R., Chen Y. Bacterial ureases in infectious diseases. Microb Infect 2000: 533-542.
10. Nomura F., Ohnishik K., Terabayshi H. et al. Effect of intrahepatic portal-systemic shunting on hepatic ammonia extraction in patients with cirrohsis. Hepatology 1994; 20: 1478-1481.
11. Schmidt-Nielsen K. Animal Physiology, 4th Edn. Cambridge: Cambridge University Press, 1994. p. 387.
12. Collins C. M., D'Orazio S. E. Bacterial ureases: structure, regulation of expression and role in pathogenesis. Mol Microbiol 1993; 9(5): 907-913.
13. Mobley H. L., Hausinger R. P. Molecular biology of microbial ureaes. Microbiol Rev 1995; 59(3): 451-480.
14. Thompson A., Visek W. J. Some effects of induction of urease immunity in patients with hepatic insufficiency. Am J Med 1963; 35: 804-809.
15. LeVeen H. H., LeVeen E. G., LeVeen R. F. Awakenings to the pathogenicity of urease and the requirement for continuous longterm therapy. Biomed Pharmacother 1994; 48: 157-166.
16. Nielsen A. E. Kemiske Data. Kobenhavn: F.A.D.Us Forlag, 1976.
17. Clausen M. R. Production and oxidation of short-chain fatty acids in the human colon. Danish Med Bull 1998; 45 (1): 51-75.
18. Mortensen P. B., Holtug K., Bonnen H., Clausen M. R. The degradation of amino acids, proteins, and blood to short-chain fatty acids in the colon is prevented by lactulose. Gastroenterology 1990; 98: 353-360.
19. Dheeraj L., Gorbach S., Levitan R. Intestinal microflora in patients with alcholic cirrhosis: urea-splitting bacteria and neomycin resistance. Gastroenterology 1972;(62): 275-279.
20. Hansen B. A., Vilstrup H. Increased intestinal hydrolysis of urea in patients: with alcoholic cirrohsis. Scand J Gastroenterol 1985;(20): 346-350.
21. Yang C. Y., Chang C. S., Chen G. H. Small-intestinal bacterial overgrowth in patients with liver cirrohsis, diagnosed with glucose H2 or CH4 breath tests. Scand J Gastroenterol 1998; 33(8): 867-871.
22. Lockwood A. H., Yap E. W., Wong W. H. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991; 11: 337-341.
23. Haussinger D., Kircheis G., Fischer R., Schliess F., vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low grade cerebra edema? J Hepatol 2000; 32: 1035-1038.
24. Blei A. Bailliere's Clin Gastroenterol 2000; 14(6): 959-974.
25. Yurdaydin C., Walsh T. J., Engler H. D. et al. Gut bacteria provide precursors of benzodiazepine receptor ligands in a rat model of hepatic encephalopathy. Brain Res 1995; 679: 42-48.
26. Zieve L., Doizaki W. M., Zieve J. Synergism between mercaptans and ammonia or fatty acids in the production of coma: a possible role for mercaptans in the pathogenesis of hepatic coma. J Lab Clin Med 1974; 83: 16-28.
27. Dagenais M. H., Bernard D., Marleau D. et at. Surgical treatment of severe postshunt hepatic encephalopathy. World Surg 1991; 15: 109-114.
28. Uribe M., Campollo O., Vargas F. Acidifying enemas (lacitiol and lactose) vs. nonacidifymg enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 1987; 7: 639-643.
29. Clausen M. R., Mortensen P. B. Lactulose, disaccharides and colonic flora. Drugs 1997; 53(6): 930-942.
30. Jenkins D., Kendall C. W., Vuksan V. Inulin, oligofructose, and intestinal function. J Nutr 1999; 129: 1431S-1433S.
31. Gibson G. R., Roberfroid M. B. Dietary modification of the human colonic microbiota-introducing the concept of prebiotic. Nutrition 1995; 125: 1401-1412.
32. Rycroft C. E., Jones M. R., Gibson G. R., Rastall R. A. A comparative in vitro evaluation of the fermentation properties of prebiotic oligosaccharides. J Appl Microbiol 2001;(91): 878-887.
33. Salminen S., Salmmen E. Lactuluose, lactic acid bacteria, intestinal microecology and mucosal protection. Scand Gastroenterol 1997; 222: 45-48.
34. Uribe M., Conn H. O. Dietary management of portal-systemic encephalopathy. In: H. O. Conn, A. Bircher (eds). Hepatic Encephalopathy: Syndromes and Therapies. Bloomington, IL: Medi-Ed Press, 1994: 331-349.
35. Herlong H. F., Maddrey W. C., Walser M. The use of ornithine salts of branched-chain ketocids in portal-systemic encephalopathy. Ann Intern Med 1980; 93: 545-550.
36. Sushma S., Dasarathy S., Tandon R. K., Jain S., Gupta S., Bhist M. S. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 1992; 16: 138-144.
37. Warren S. E., Mitas J. A., Swerdlin A. H. Hypernatremia in hepatic failure. JAMA 1980; 243: 1257-1260.
38. Lost S., Sonne J., Dossing M., Andreasen P. B. Metronidazole pharmokinetics in patients with hepatic encephalopathy. Scand J Gastroenterol 1987; 22: 117-123.
39. Gerber T., Schomerus H. Hepatic encephalopathy in liver cirrhosis. Drugs 2000; 60(6): 1353-1370.
40. Gibson G. R., Wang X. Regulatory effects of bifidobacteria on the growth of other colonic bacteria. Appl Bacteriol 1994; 77(4): 412-420.
41. Madsen K. L., Cornish A., Soper P. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121: 580-591.
42. Kanauchi O., Fujiyama Y., Mitsuyama K. et al. Incresed growth of bifidobacterium and eubacterium by germinated barely foodstuff, accompanied by enhanced butyrate production in healthy volunteers. Int J Mol Med 1999; 3(2): 175-179.
43. Adachi Y., Moore L. E., Bradford B. U., Gao W., Thurman R. G. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995; 108(1): 218-224.
44. Nanj A. A., Khettry U., Sadrzadeh S. M. H. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver disease. Proc Soc Exp Biol Med 1994; 205: 243-247.
45. Yang S. Q., Lin H. Z., Lane M. D., Clemens M., Diehl A. M. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. PNAS 1997; 94(6): 2557-2562.
46. Enomoto N., Ikejima K., Bradford B. U. et al. Hepatology: microciroalation and pathogenesis of alcoholic liver injury. Role of Kupffer cells and gut-derived endotoxins in alcoholic liver injury. J Gastroenterol Hepatol 2000; 15(suppl): D20-D25.
47. Yang S. Q., Lin H., Diehl A. M. Fatty liver vulnerability to endotoxin-induced damage despite NF-kappaB induction and inhibited caspase 3 activation. Am J Physiol Gastrointest Liver Physiol 2001; 281(2): G382-G392.
48. Li Z., Yang S. Q., Lin H. Z. et al. Probiotics and anti-TNF antibodies inhibit inflammatory activity and improve non-alcoholic fatty liver disease in ob/ob mice. Abstract DDW 2002, in review.
49. Hida M., Aiba Y., Sawamura S. et al. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996; 74: 349-355.
50. Simenhoff M. L., Dunn S. R., Zollner G. P. et al. Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus. Miner Electrolyte Metab 1996; 22(1-3): 92-96.
51. Rolfe R. D. The role of probiotic cultures in the control of gastrointestinal health. J Nutr 2000; 130(2s suppl): 396s-402s.
52. Gionchetti P., Rizzello F., Venturi A., Campieri M. Probiotics in infective diarrhea and inflammatory bowel diseases. J Gastroenterol Hepatol 2000; 15: 489-493.
53. Seeff L., Lindsay K. L., Bacon B. R., Kresina T. F., Hoofnagle J. H. Complementary and alternative medicine in chronic liver disease. Hepatology 2001; 34(3): 595-603.
54. Ferenci P. Hepatic encephalopathy; treatment. In: J. W. D. McDonald, A. K. Burroughs, B. G. Feagan (eds). Evidence Based Gastroenterology and Hepatology. London: British Medical Journal-Books, 1999: 443-455.
55. Ferenci P., Lockwood A., Mullen K., Tarter R., Weissenborn K., Blei A. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification. Final Report of the Working Party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatololgy 2002; 35: 716-721.
56. Macbeth W., Kass E., McDermott W. Treatment of hepatic encephalopathy by alteration of intestinal flora with Lactobacillus acidophilus. Lancet 1965; 1: 399-403.
57. Read A. E., McCarthy C. F., Heaton K. W., Laidlaw J. Lactobacillus acidophilus (Enpac) in treatment of hepatic encephalopathy. BMJ 1966; 1: 1267-1269.
58. Loguerico C., Abbiati R., Rinaldi M., Romano A., Del Vecchio Blanco C., Coltori M. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 1995; 23: 39-46.
59. Loguercio C., Del Vecchio Blanco C., Coltorti M. Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. J Int Med Res 1987; 15(6): 335-343.
60. Venturi A., Gionchetti P., Rizzello F. et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1103-1108.
61. Brigidi P., Vitali B., Swennen E., Bazzocchi G., Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 2001; 152: 735-741.
62. Bianchi-Salvadori B., Vesely R., Ferrari A., Canzi E., Casiraghi C., Brighenti F. Behaviour of the pharmaceutical probiotic preparation VSL#3 in human ileostomy effluent containing its own natural elements. New Microbiol 2001; 24(1): 23-33.
63. Madsen K. L., Cornish A., Soper P et al. Probiotic bacteria enhance routine and human intestinal epithelial barrier function. Gastroenterology 2001; 121: 580-591.